Cargando…
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence
IMPORTANCE: Substantial heterogeneity exists in treatment recommendations across molecular tumor boards (MTBs), especially for biomarkers with low evidence levels; therefore, the learning program is essential. OBJECTIVE: To determine whether a learning program sharing treatment recommendations for b...
Autores principales: | Sunami, Kuniko, Naito, Yoichi, Saigusa, Yusuke, Amano, Toraji, Ennishi, Daisuke, Imai, Mitsuho, Kage, Hidenori, Kanai, Masashi, Kenmotsu, Hirotsugu, Komine, Keigo, Koyama, Takafumi, Maeda, Takahiro, Morita, Sachi, Sakai, Daisuke, Hirata, Makoto, Ito, Mamoru, Kozuki, Toshiyuki, Sakashita, Hiroyuki, Horinouchi, Hidehito, Okuma, Yusuke, Takashima, Atsuo, Kubo, Toshio, Hironaka, Shuichi, Segawa, Yoshihiko, Yakushijin, Yoshihiro, Bando, Hideaki, Makiyama, Akitaka, Suzuki, Tatsuya, Kinoshita, Ichiro, Kohsaka, Shinji, Ohe, Yuichiro, Ishioka, Chikashi, Yamamoto, Kouji, Tsuchihara, Katsuya, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690580/ https://www.ncbi.nlm.nih.gov/pubmed/38032680 http://dx.doi.org/10.1001/jamaoncol.2023.5120 |
Ejemplares similares
-
Chronological improvement in precision oncology implementation in Japan
por: Sunami, Kuniko, et al.
Publicado: (2022) -
Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors
por: Imai, Mitsuho, et al.
Publicado: (2022) -
Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan
por: Naito, Yoichi, et al.
Publicado: (2022) -
The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan
por: Sunami, Kuniko, et al.
Publicado: (2021) -
Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2020)